Quinstreet Insider Trades $1.2M In Company Stock
Douglas Valenti, Chief Executive Officer at Quinstreet (NASDAQ:QNST), made a large insider sell on October 5, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Valenti sold 69,427 shares of Quinstreet at prices ranging from $17.37 to $17.87. The total transaction amounted to $1,222,842.
Following the transaction, Valenti still owns 2,754,496 shares of the company, worth $47,487,511.
Quinstreet shares are trading down 1.32% at $17.24 at the time of this writing on Wednesday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Transaction Codes To Focus On
Investors prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
Check Out The Full List Of Quinstreet's Insider Trades.
See more from Benzinga
Executive Board Chairman Of Patrick Industries Makes 0K Sale
Chief Commercial Officer Of Corcept Therapeutics Trades 0K In Company Stock
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
